CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC — Stella

Recruiting

Back to Adenoid Cystic Carcinoma trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

United States

Dana Farber Cancer Institute, Boston, Massachusetts

Key details

Phase

Early testing / Safety & dosing

Sponsor

Glenn J. Hanna

Collaborators

Adenoid Cystic Carcinoma Research Foundation, Cellestia Biotech AG

Enrollment target

~32 participants

Started

June 2023

Primary completion

June 2026

Age range

18 Years and older

Last updated June 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov